World’s First COVID-19 Drug Based on Human Immunoglobulin Developed from Plasma of Recovered Patients
|
By HospiMedica International staff writers Posted on 14 Sep 2021 |

Illustration
The world’s first drug based on human immunoglobulin being developed from plasma of recovered patients could be effective on COVID-19 patients with mild conditions.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) is developing two medicines for the treatment of COVID-19 based on human immunoglobulin and monoclonal antibody. Both the drugs could reduce the impact of the novel coronavirus in infected people and will be effective on patients with mild COVID-19, according to a report by the Global Times.
The first drug being developed from plasma of recovered COVID-19 patients or vaccinated uninfected people contains high-potency SARS-COV-2 neutralizing antibodies. The drug has demonstrated significant relief of symptoms and damage caused by SARS-COV-2 in pre-clinical studies and animal tests. The new drug containing a high level of neutralizing antibodies to the novel coronavirus is all set to soon enter Phase 3 clinical trials.
The second COVID-19 drug under development is based on a potent monoclonal antibody against the Delta variant discovered by researchers at Sinopharm. The monoclonal antibody is capable of effectively blocking the binding of the novel coronavirus to the Angiotensin-converting enzyme 2 which is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. According to Sinopharm, the antibody can prevent the SARS-COV-2 virus from infecting human cells.
Related Links:
China National Pharmaceutical Group Co., Ltd.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Explainable AI Tool Identifies High-Risk Patients Before Heart Attack Reperfusion
Intramyocardial hemorrhage is bleeding within the heart muscle that can occur after blood flow is restored during heart attack treatment. It affects about 40% of patients treated for ST-segment elevation... Read more
AI Tools Show Potential to Detect Subtle Signs of Interval Breast Cancer
Interval breast cancers, diagnosed after a negative screening mammogram and before the next scheduled exam, remain an important measure of screening performance and are often more aggressive.... Read moreCritical Care
view channel
Scotland Adopts Respiratory Infection Control Guidance Informed by Aerosol Research
Preventing respiratory infection transmission in hospitals remains a core patient and staff safety priority. Many precautions have hinged on the assumption that certain clinical interventions create high-risk... Read more
Hospital Safety Program Linked to 65% Reduction in MRSA Bloodstream Infections
Hospital-onset methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections are difficult to treat and increase morbidity, mortality, and costs for acutely ill patients. Vulnerability rises... Read moreSurgical Techniques
view channel
FDA Clears Integrated Platform for Real-Time Cardiac Imaging and Catheter Guidance
Catheter-based treatment of cardiac arrhythmias relies on precise, real-time visualization and navigation for safe, accurate therapy delivery. Yet electrophysiology teams often use separate imaging, mapping,... Read more
New Microcatheter Enhances Lesion Crossing in Complex Coronary Interventions
Crossing resistant coronary lesions during percutaneous coronary intervention can be hindered by tortuous or calcified anatomy, delaying therapy and complicating device delivery. Many microcatheters rely... Read more
Integrated Perioperative Care Model Improves Recovery in Older Surgical Patients
Older adults undergoing major surgery often experience anxiety and depression that can slow rehabilitation and worsen functional recovery. Many also take central nervous system–active medications that... Read more
Integrated PET/MRI and EEG Improves Presurgical Lesion Localization in Pediatric Focal Epilepsy
Focal epilepsy, in which seizures arise from a discrete brain region, requires precise lesion localization before surgery. Many children have negative or inconclusive magnetic resonance imaging (MRI),... Read morePatient Care
view channel
Virtual Reality Helps Claustrophobic Patients Complete Cardiac PET/CT Scans
Anxiety and claustrophobia—intense fear of confined spaces—often prevent patients from completing cardiac positron emission tomography/computed tomography (PET/CT). Aborted scans delay diagnosis, consume... Read more
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read moreMedical Imaging
view channel
AI Models Evaluated for Spotting Ischemic Stroke Lesions on Routine MRI
Rapid detection of ischemic stroke on brain MRI is essential because treatment benefit declines with time. Many centers first acquire contrast-free MRI FLAIR sequences because they are quick and broadly... Read more
Noninvasive MRI Spectroscopy Classifies Pediatric Medulloblastoma Molecular Subgroups
Medulloblastoma, the most common malignant pediatric brain tumor, requires precise molecular classification to guide therapy and predict outcomes. Current subgrouping typically depends on surgical sampling... Read moreHealth IT
view channel
Registry-Driven Digital Outreach Boosts Use of Heart Failure Medicines
Heart failure affects more than 64 million people worldwide and is linked to high mortality, reduced quality of life, and heavy healthcare use. Although sodium-glucose cotransporter 2 inhibitors are proven... Read more
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read morePoint of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read moreBusiness
view channel
Robotic Single-Port System Gains CE Mark for Transvaginal Gynecologic Procedures
Intuitive (Sunnyvale, CA, USA) announced that it has received CE mark approval for use of the da Vinci SP Single Port surgical system in transvaginal gynecologic procedures, marking the first such indication... Read more








